Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
09/19/2022 | Press release | Distributed by Public on 09/19/2022 05:03
Please select the service you want to use:
Smartlinks | Alnylam Pharmaceuticals Inc. | News | Health | Local News | Company News | Public Companies | Biotechnology and Medical Research Companies | London Stock Exchange (LSE) | Börse Frankfurt | Bolsa de Valores de São Paulo (B3) | Börse Düsseldorf | Börse München | Börse Stuttgart | Bolsa Mexicana de Valores (BMV) | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Börse Hamburg | Börse Hannover | Nasdaq Global Select Market | BZX Exchange | BYX Exchange | EDGA Exchange | EDGX Exchange | NYSE National | Nasdaq BX | Nasdaq PSX | NYSE Chicago | Bolsa Institucional de Valores (BIVA)
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact